Ann: Imugene PD1-Vaxx Update, page-26

I know there is frustration with the SP woes of late - understandable.

However, we we get information that sees the active results of a treatment that gives a late stage patient 3 years of cancer free life, there not only is a sense that IMU is a good investment but an incredible opportunity for patients.

Last week marked 1000 days cancer free for a patient with late-stage NSCLC who was
recruited and dosed in December 2020. This week Professor Michael Boyer M.D., MBBS,
FRACP, PhD, Chris O’Brien Lifehouse Hospital will present a trial-in-progress poster in
person at the IASLC 2023 World Conference on Lung Cancer (WCLC 2023) in Singapore.
The poster presentation can be downloaded from Imugene’s website,
https://www.imugene.com/conference-presentations
Imugene MD & CEO Leslie Chong said: “Attaining the key Japanese patent, on top of gaining
protection in the USA this year, is a very important milestone. Recruitment in the Phase 1
IMUGENE LIMITED ACN 009 179 551 2
PD1-Vaxx trial, as monotherapy or in combination with atezolizumab in adults with NonSmall Cell Lung Cancer, has increased markedly recently with strong interest from new
clinical sites to participate in this innovative study